Medical device maker Integer Holdings to go private in US$5.7B KKR acquisition

USA—Integer Holdings has agreed to be acquired by an affiliate of investment funds managed by KKR in an all-cash transaction that values the medical device manufacturer at US$5.7 billion.

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

The offer represents a 51.8% premium to Integer’s closing share price on 29 April 2026, the day before the company announced that it was conducting a strategic review.

The transaction also represents a 28.8% premium to Integer’s 30-day volume-weighted average share price as of 31 July 2026.

Strategic review led to KKR deal

Integer Holdings’ Board of Directors has unanimously approved the transaction and is recommending that shareholders vote in favour of the agreement.

The deal follows a comprehensive strategic review that began on 30 April 2026.

During the process, the board worked with the company’s management team and external advisers to assess several strategic alternatives before selecting KKR’s proposal as the preferred option.

Integer Holdings president and CEO Payman Khales said the transaction represents an important milestone for the company and reflects the strength of the business and its workforce.

He added that the agreement recognises Integer’s engineering and manufacturing capabilities, dedicated employees and long-term growth prospects while providing shareholders with immediate and certain value.

Khales also said KKR’s healthcare expertise, long-term investment approach and focus on strategic growth made it a suitable partner for Integer as the company enters its next phase.

Integer to become privately held

Following completion of the transaction, Integer Holdings is expected to become a privately held company, with its shares delisted from the New York Stock Exchange.

KKR has also indicated that it intends to establish an employee ownership programme at Integer.

The initiative would be consistent with KKR’s approach at several of its other portfolio companies and would give employees an ownership interest in the business.

Integer Holdings develops and manufactures medical devices and components used in a range of healthcare applications. The company’s capabilities include engineering, manufacturing and the development of products for the medical device industry.

Deal awaits approvals

Completion of the acquisition remains subject to approval by Integer Holdings’ shareholders and the receipt of required regulatory clearances.

The transaction is expected to close by the end of 2026, subject to the satisfaction of the applicable closing conditions.

Once completed, the acquisition will take Integer Holdings private and end its listing on the New York Stock Exchange.